Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Thalassemia 1Primary Myelofibrosis 1Polycythemia Vera 1Leukemia, Myeloid, Acute 1Graft vs Host Disease 1Bronchiolitis Obliterans Syndrome 1

Interventions

venetoclax 28Cytarabine 25Azacitidine 23Specimen Handling 21fludarabine 15Biopsy 13Injections 12Daunorubicin 11Cyclophosphamide 11fludarabine phosphate 10decitabine and cedazuridine drug combination 9Whole-Body Irradiation 9CPX-351 8Mycophenolic Acid 7Idarubicin 7Granulocyte Colony-Stimulating Factor 7Gemtuzumab 7ivosidenib 6Tacrolimus 6Stem Cell Transplantation 6Filgrastim 6Busulfan 6enasidenib 5X-Rays 5Melphalan 5Etoposide 5Decitabine 5Cyclosporine 5ruxolitinib 4olutasidenib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × Panobinostat × 30 days × Clear all
NCT02386800 2026-05-27

CINC424A2X01B Rollover Protocol

Novartis

Phase 4 Active not recruiting
279 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Polycythemia Vera, Thalassemia, Leukemia, Myeloid, Acute, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡